Skip to main content

Refine your results

Filters

Displaying 1941 - 1960 of 2291

Feb13
Event

Broadband Connectivity Competition Policy

-
The FTC hosted a public workshop on that brought together experts from business, government, and the technology sector, consumer advocates, and academics to explore competition and consumer protection...
Press Release

FTC Challenges Hospira/Mayne Pharma Deal

Date
To Protect Competition, Companies Must Sell Assets for Five Generic Injectable Drugs The Federal Trade Commission today announced its challenge to Hospira Inc.’s (Hospira) proposed $2 billion...
Cases and Proceedings

Watson Pharmaceuticals, Inc. and Andrx Corporation., In the Matter of

A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham Holdings, divest Andrx’s right to develop, make, and market generic extended release tablets that correct the effects of type 2 diabetes, and divest Andrx’s rights and assets related to the developing and marketing of 11 generic oral contraceptives.

There is a related federal proceeding and two related administrative proceedings:

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0610139
Docket Number
C-4172

Displaying 1941 - 1960 of 2291

Return to top